Curzio RÃ¼egg

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1982320/publications.pdf

Version: 2024-02-01

119	6,915	50276	62596
papers	citations	46 h-index	80 g-index

121	121	121	10994
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Polymersomesâ€Mediated Delivery of CSF1R Inhibitor to Tumor Associated Macrophages Promotes M2 to M1â€Like Macrophage Repolarization. Macromolecular Bioscience, 2022, 22, .	4.1	6
2	MAGI1 localizes to mature focal adhesion and modulates endothelial cell adhesion, migration and angiogenesis. Cell Adhesion and Migration, 2021, 15, 126-139.	2.7	11
3	Dormant Tumor Cell Vaccination: A Mathematical Model of Immunological Dormancy in Triple-Negative Breast Cancer. Cancers, 2021, 13, 245.	3.7	11
4	Gain of HIF1 Activity and Loss of miRNA let-7d Promote Breast Cancer Metastasis to the Brain via the PDGF/PDGFR Axis. Cancer Research, 2021, 81, 594-605.	0.9	18
5	MAGI1, a Scaffold Protein with Tumor Suppressive and Vascular Functions. Cells, 2021, 10, 1494.	4.1	10
6	Recent Antiâ€angiogenic Drug Discovery Efforts To Combat Cancer. ChemistrySelect, 2021, 6, 5689-5700.	1.5	3
7	Circulating immune cell populations related to primary breast cancer, surgical removal, and radiotherapy revealed by flow cytometry analysis. Breast Cancer Research, 2021, 23, 64.	5.0	9
8	Membrane-Interacting DNA Nanotubes Induce Cancer Cell Death. Nanomaterials, 2021, 11, 2003.	4.1	8
9	Targeting OLFML3 in Colorectal Cancer Suppresses Tumor Growth and Angiogenesis, and Increases the Efficacy of Anti-PD1 Based Immunotherapy. Cancers, 2021, 13, 4625.	3.7	12
10	Mathematical modeling approach of cancer immunoediting reveals new insights in targeted-therapy and timing plan of cancer treatment. Chaos, Solitons and Fractals, 2021, 152, 111349.	5.1	3
11	Î²-Arrestin1 and Î²-Arrestin2 Are Required to Support the Activity of the CXCL12/HMGB1 Heterocomplex on CXCR4. Frontiers in Immunology, 2020, 11, 550824.	4.8	13
12	CD47 Promotes Age-Associated Deterioration in Angiogenesis, Blood Flow and Glucose Homeostasis. Cells, 2020, 9, 1695.	4.1	34
13	The Crosstalk between FAK and Wnt Signaling Pathways in Cancer and Its Therapeutic Implication. International Journal of Molecular Sciences, 2020, 21, 9107.	4.1	28
14	Targeting the Extra-Cellular Matrixâ€"Tumor Cell Crosstalk for Anti-Cancer Therapy: Emerging Alternatives to Integrin Inhibitors. Frontiers in Oncology, 2020, 10, 1231.	2.8	18
15	DNA Origami as Emerging Technology for the Engineering of Fluorescent and Plasmonic-Based Biosensors. Materials, 2020, 13, 2185.	2.9	27
16	MAGI1, a New Potential Tumor Suppressor Gene in Estrogen Receptor Positive Breast Cancer. Cancers, 2020, 12, 223.	3.7	15
17	Detection of HER2⁺ Breast Cancer Cells using Bioinspired DNAâ€Based Signal Amplification. ChemMedChem, 2020, 15, 661-666.	3.2	14
18	Emodin Inhibits Inflammation, Carcinogenesis, and Cancer Progression in the AOM/DSS Model of Colitis-Associated Intestinal Tumorigenesis. Frontiers in Oncology, 2020, 10, 564674.	2.8	38

#	Article	IF	Citations
19	Are Integrins Still Practicable Targets for Anti-Cancer Therapy?. Cancers, 2019, 11, 978.	3.7	128
20	Breast Cancer Stem Cells with Tumor- versus Metastasis-Initiating Capacities Are Modulated by TGFBR1 Inhibition. Stem Cell Reports, 2019, 13, 1-9.	4.8	24
21	MAGI1 Mediates eNOS Activation and NO Production in Endothelial Cells in Response to Fluid Shear Stress. Cells, 2019, 8, 388.	4.1	38
22	A Bio-Inspired Amplification Cascade for the Detection of Rare Cancer Cells. Chimia, 2019, 73, 63-68.	0.6	2
23	Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer. Oncogene, 2019, 38, 2814-2829.	5.9	85
24	Inhibition of host NOX1 blocks tumor growth and enhances checkpoint inhibitorâ€“based immunotherapy. Life Science Alliance, 2019, 2, e201800265.	2.8	23
25	Not just Fundamental Research: Education, Equal Opportunities, Knowledge and Technology Transfer, and Communication at the NCCR Bio-Inspired Materials. Chimia, 2019, 73, 86.	0.6	0
26	PKB/Akt-dependent regulation of inflammation in cancer. Seminars in Cancer Biology, 2018, 48, 62-69.	9.6	87
27	Obesity promotes the expansion of metastasis-initiating cells in breast cancer. Breast Cancer Research, 2018, 20, 104.	5.0	68
28	Consensus guidelines for the use and interpretation of angiogenesis assays. Angiogenesis, 2018, 21, 425-532.	7.2	429
29	A rational and iterative process for targeted nanoparticle design and validation. Colloids and Surfaces B: Biointerfaces, 2018, 171, 579-589.	5.0	6
30	Characterization and In Vivo Validation of a Three-Dimensional Multi-Cellular Culture Model to Study Heterotypic Interactions in Colorectal Cancer Cell Growth, Invasion and Metastasis. Frontiers in Bioengineering and Biotechnology, 2018, 6, 97.	4.1	30
31	TGFÎ², Fibronectin and Integrin Î±5Î²1 Promote Invasion in Basal Cell Carcinoma. Journal of Investigative Dermatology, 2018, 138, 2432-2442.	0.7	29
32	Baicalein inhibits acinarâ€toâ€ductal metaplasia of pancreatic acinal cell AR42J via improving the inflammatory microenvironment. Journal of Cellular Physiology, 2018, 233, 5747-5755.	4.1	18
33	Arginase inhibition suppresses lung metastasis in the 4T1 breast cancer model independently of the immunomodulatory and anti-metastatic effects of VEGFR-2 blockade. OncoImmunology, 2017, 6, e1316437.	4.6	40
34	Targeting tumor-associated macrophages by anti-tumor Chinese materia medica. Chinese Journal of Integrative Medicine, 2017, 23, 723-732.	1.6	3
35	The matricellular protein CYR61 promotes breast cancer lung metastasis by facilitating tumor cell extravasation and suppressing anoikis. Oncotarget, 2017, 8, 9200-9215.	1.8	52
36	mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition. Oncotarget, 2017, 8, 69204-69218.	1.8	21

#	Article	IF	Citations
37	Development and Clinical Validation of a Blood Test Based on 29-Gene Expression for Early Detection of Colorectal Cancer. Clinical Cancer Research, 2016, 22, 4604-4611.	7.0	26
38	TLR7-based cancer immunotherapy decreases intratumoral myeloid-derived suppressor cells and blocks their immunosuppressive function. OncoImmunology, 2016, 5, e1230578.	4.6	65
39	Computational modeling of shear forces and experimental validation of endothelial cell responses in an orbital well shaker system. Computer Methods in Biomechanics and Biomedical Engineering, 2016, 19, 581-590.	1.6	31
40	The matricellular protein CYR61 interferes with normal pancreatic islets architecture and promotes pancreatic neuroendocrine tumor progression. Oncotarget, 2016, 7, 1663-1674.	1.8	18
41	Bevacizumab specifically decreases elevated levels of circulating KIT+CD11b+ cells and IL-10 in metastatic breast cancer patients. Oncotarget, 2016, 7, 11137-11150.	1.8	14
42	Angiogenic Activity of Breast Cancer Patientsâ€™ Monocytes Reverted by Combined Use of Systems Modeling and Experimental Approaches. PLoS Computational Biology, 2015, 11, e1004050.	3.2	18
43	An immature B cell population from peripheral blood serves as surrogate marker for monitoring tumor angiogenesis and anti-angiogenic therapy in mouse models. Angiogenesis, 2015, 18, 327-345.	7.2	10
44	Mechanism of irradiationâ€induced mammary cancer metastasis: A role for SAPâ€dependent Mkl1 signaling. Molecular Oncology, 2015, 9, 1510-1527.	4.6	19
45	Discovery of a 29-Gene Panel in Peripheral Blood Mononuclear Cells for the Detection of Colorectal Cancer and Adenomas Using High Throughput Real-Time PCR. PLoS ONE, 2015, 10, e0123904.	2.5	21
46	Fibroblast surface-associated FGF-2 promotes contact-dependent colorectal cancer cell migration and invasion through FGFR-SRC signaling and integrin Î±vÎ²5-mediated adhesion. Oncotarget, 2015, 6, 14300-14317.	1.8	67
47	A novel gene expression signature in peripheral blood mononuclear cells for early detection of colorectal cancer. Alimentary Pharmacology and Therapeutics, 2014, 39, 507-517.	3.7	21
48	Synthesis of a nonâ€peptidic PET tracer designed for Î±₅Î²₁ integrin receptor. Journal of Labelled Compounds and Radiopharmaceuticals, 2014, 57, 365-370.	1.0	2
49	Fragment N2, a caspase-3-generated RasGAP fragment, inhibits breast cancer metastatic progression. International Journal of Cancer, 2014, 135, 242-247.	5.1	16
50	Neutrophil expression of ICAM1, CXCR1, and VEGFR1 in patients with breast cancer before and after adjuvant chemotherapy. Anticancer Research, 2014, 34, 4693-9.	1.1	5
51	Synthesis and in vitro evaluation of a novel radioligand for Î±vÎ²3 integrin receptor imaging: [18F]FPPA-c(RGDfK). Bioorganic and Medicinal Chemistry Letters, 2013, 23, 6068-6072.	2.2	7
52	The Î±VÎ²3/Î±VÎ²5 integrin inhibitor cilengitide augments tumor response to melphalan isolated limb perfusion in a sarcoma model. International Journal of Cancer, 2013, 132, 2694-2704.	5.1	9
53	Akt/PKB-Mediated Phosphorylation of Twist1 Promotes Tumor Metastasis via Mediating Cross-Talk between PI3K/Akt and TGF-Î² Signaling Axes. Cancer Discovery, 2012, 2, 248-259.	9.4	182
54	Inhibition of the Kit Ligand/c-Kit Axis Attenuates Metastasis in a Mouse Model Mimicking Local Breast Cancer Relapse after Radiotherapy. Clinical Cancer Research, 2012, 18, 4365-4374.	7.0	64

#	Article	IF	Citations
55	Molecular Pathways: Emerging Pathways Mediating Growth, Invasion, and Metastasis of Tumors Progressing in an Irradiated Microenvironment. Clinical Cancer Research, 2012, 18, 5196-5202.	7.0	68
56	Concepts of metastasis in flux: The stromal progression model. Seminars in Cancer Biology, 2012, 22, 174-186.	9.6	75
57	New insights into the mechanisms of organ-specific breast cancer metastasis. Seminars in Cancer Biology, 2012, 22, 226-233.	9.6	133
58	Targeting Vascular NADPH Oxidase 1 Blocks Tumor Angiogenesis through a PPARÎ± Mediated Mechanism. PLoS ONE, 2011, 6, e14665.	2.5	128
59	Proangiogenic Factor PlGF Programs CD11b+ Myelomonocytes in Breast Cancer during Differentiation of Their Hematopoietic Progenitors. Cancer Research, 2011, 71, 3781-3791.	0.9	32
60	Radiation-induced modifications of the tumor microenvironment promote metastasis. Bulletin Du Cancer, 2011, 98, E47-E57.	1.6	34
61	Emerging paradigms and questions on pro-angiogenic bone marrow-derived myelomonocytic cells. International Journal of Developmental Biology, 2011, 55, 527-534.	0.6	19
62	Autologous stem cell transplantation: leukapheresis product has anti-angiogenic effects in vivo correlating with neutrophil-derived VEGFR1. Anticancer Research, 2011, 31, 3115-24.	1.1	4
63	Targeting integrins in malignant glioma. Targeted Oncology, 2010, 5, 175-181.	3.6	83
64	Fc block treatment, dead cells exclusion, and cell aggregates discrimination concur to prevent phenotypical artifacts in the analysis of subpopulations of tumorâ€infiltrating CD11b⁺ myelomonocytic cells. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2010, 77A, 1082-1090.	1.5	18
65	Radiotherapy Suppresses Angiogenesis in Mice through TGF-Î²RI/ALK5-Dependent Inhibition of Endothelial Cell Sprouting. PLoS ONE, 2010, 5, e11084.	2.5	68
66	Low Doses of Ionizing Radiation Promote Tumor Growth and Metastasis by Enhancing Angiogenesis. PLoS ONE, 2010, 5, e11222.	2.5	157
67	Ataxia Telangiectasia Mutated (ATM) Inhibition Transforms Human Mammary Gland Epithelial Cells. Journal of Biological Chemistry, 2010, 285, 13092-13106.	3.4	18
68	Tenascinâ€W is a specific marker of gliomaâ€associated blood vessels and stimulates angiogenesisin vitro. FASEB Journal, 2010, 24, 778-787.	0.5	59
69	Vascular Integrins: Therapeutic and Imaging Targets of Tumor Angiogenesis. Recent Results in Cancer Research, 2010, 180, 83-101.	1.8	57
70	The Integrin Antagonist Cilengitide Activates Î±VÎ²3, Disrupts VE-Cadherin Localization at Cell Junctions and Enhances Permeability in Endothelial Cells. PLoS ONE, 2009, 4, e4449.	2.5	118
71	Modulation of Angiogenic and Inflammatory Response in Glioblastoma by Hypoxia. PLoS ONE, 2009, 4, e5947.	2.5	95
72	Thalidomide in Small Cell Lung Cancer: Wrong Drug or Wrong Disease?. Journal of the National Cancer Institute, 2009, 101, 1034-1035.	6.3	7

#	Article	IF	Citations
73	Profiling of Tâ€cell receptor signaling complex assembly in human CD4 Tâ€lymphocytes using RP protein arrays. Proteomics, 2009, 9, 299-309.	2.2	3
74	Myeloid Cells Contribute to Tumor Lymphangiogenesis. PLoS ONE, 2009, 4, e7067.	2.5	108
75	The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochemistry and Cell Biology, 2008, 130, 1091-1103.	1.7	425
76	Proteomic analysis of membrane rafts of melanoma cells identifies protein patterns characteristic of the tumor progression stage. Proteomics, 2008, 8, 4733-4747.	2.2	38
77	Tenascinâ€W, a new marker of cancer stroma, is elevated in sera of colon and breast cancer patients. International Journal of Cancer, 2008, 122, 2454-2461.	5.1	50
78	Compartmentalization in membrane rafts defines a pool of N-cadherin associated with catenins and not engaged in cellâ€“cell junctions in melanoma cells. Journal of Cellular Biochemistry, 2008, 103, 957-971.	2.6	5
79	CYR61 and Î±VÎ²5 Integrin Cooperate to Promote Invasion and Metastasis of Tumors Growing in Preirradiated Stroma. Cancer Research, 2008, 68, 7323-7331.	0.9	109
80	Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?. Nature Clinical Practice Oncology, 2008, 5, 378-391.	4.3	144
81	Omics meets hypothesis-driven research. Partnership for innovative discoveries in vascular biology and angiogenesis. Thrombosis and Haemostasis, 2008, 100, 738-46.	3.4	6
82	Integrin Inhibitors Reaching the Clinic. Journal of Clinical Oncology, 2007, 25, 1637-1638.	1.6	116
83	N-cadherin as a therapeutic target in cancer. Expert Opinion on Investigational Drugs, 2007, 16, 451-465.	4.1	96
84	The Chemokine Receptor CXCR4 Strongly Promotes Neuroblastoma Primary Tumour and Metastatic Growth, but not Invasion. PLoS ONE, 2007, 2, e1016.	2.5	52
85	Anti-angiogenic therapies in cancer: achievements and open questions. Bulletin Du Cancer, 2007, 94, 753-62.	1.6	16
86	Complete and long-lasting regression of disseminated multiple skin melanoma metastases under treatment with cyclooxygenase-2 inhibitor. Melanoma Research, 2006, 16, 263-265.	1.2	36
87	Antiangiogenic peptides and proteins: From experimental tools to clinical drugs. Biochimica Et Biophysica Acta: Reviews on Cancer, 2006, 1765, 155-177.	7.4	31
88	Monitoring multiple angiogenesis-related molecules in the blood of cancer patients shows a correlation between VEGF-A and MMP-9 levels before treatment and divergent changes after surgical vs. conservative therapy. International Journal of Cancer, 2006, 118, 755-764.	5.1	30
89	Vascular Integrins in Tumor Angiogenesis: Mediators and Therapeutic Targets. Endothelium: Journal of Endothelial Cell Research, 2006, 13, 113-135.	1.7	149
90	Leukocytes, inflammation, and angiogenesis in cancer: fatal attractions. Journal of Leukocyte Biology, 2006, 80, 682-684.	3.3	61

#	Article	IF	Citations
91	Expressed isolated integrin Î²1 subunit cytodomain induces endothelial cell death secondary to detachment. Thrombosis and Haemostasis, 2005, 94, 1060-1070.	3.4	16
92	Isolated integrin Î²3 subunit cytoplasmic domains require membrane anchorage and the NPXY motif to recruit to adhesion complexes but do not discriminate between Î²1â€“ and Î²3-positive complexes. Thrombosis and Haemostasis, 2005, 94, 155-166.	3.4	6
93	Integrin-mediated Adhesion and Soluble Ligand Binding Stabilize COX-2 Protein Levels in Endothelial Cells by Inducing Expression and Preventing Degradation. Journal of Biological Chemistry, 2005, 280, 1077-1085.	3.4	48
94	Homing Phenotypes of Tumor-Specific CD8 T Cells Are Predetermined at the Tumor Site by Crosspresenting APCs. Immunity, 2005, 22, 175-184.	14.3	209
95	Expressed isolated integrin beta1 subunit cytodomain induces endothelial cell death secondary to detachment. Thrombosis and Haemostasis, 2005, 94, 1060-70.	3.4	3
96	Endothelial cell integrins and COX-2: mediators and therapeutic targets of tumor angiogenesis. Biochimica Et Biophysica Acta: Reviews on Cancer, 2004, 1654, 51-67.	7.4	62
97	Manganese-induced integrin affinity maturation promotes recruitment of Î±VÎ²3 integrin to focal adhesions in endothelial cells: evidence for a role of phosphatidylinositol 3-kinase and Src. Thrombosis and Haemostasis, 2004, 92, 151-161.	3.4	42
98	Non steroidal antiâ€inflammatory drugs and COXâ€2 inhibitors as antiâ€cancer therapeutics: hypes, hopes and reality. Annals of Medicine, 2003, 35, 476-487.	3.8	67
99	The Î²1 and Î²3 Integrins Promote T Cell Receptor-mediated Cytotoxic T Lymphocyte Activation. Journal of Biological Chemistry, 2003, 278, 26983-26991.	3.4	59
100	Zoledronate Sensitizes Endothelial Cells to Tumor Necrosis Factor-induced Programmed Cell Death. Journal of Biological Chemistry, 2003, 278, 43603-43614.	3.4	119
101	Regulation of endothelial cell integrin function and angiogenesis by COX-2, cAMP and Protein Kinase A. Thrombosis and Haemostasis, 2003, 90, 577-585.	3.4	43
102	The Quest for Surrogate Markers of Angiogenesis: A Paradigm for Translational Research in Tumor Angiogenesis and Anti- Angiogenesis Trials. Current Molecular Medicine, 2003, 3, 673-691.	1.3	41
103	Prostaglandin E2 Promotes Integrin Î±VÎ²3-dependent Endothelial Cell Adhesion, Rac-activation, and Spreading through cAMP/PKA-dependent Signaling. Journal of Biological Chemistry, 2002, 277, 45838-45846.	3.4	132
104	Modulation of cdk2, cyclin D1, p16INK4a, p21WAF and p27Kip1 expression in endothelial cells by TNF/IFN gamma. Anticancer Research, 2002, 22, 3159-63.	1.1	21
105	Inhibition of tumor angiogenesis by non-steroidal anti-inflammatory drugs: emerging mechanisms and therapeutic perspectives. Drug Resistance Updates, 2001, 4, 314-321.	14.4	50
106	NSAIDs inhibit Î±VÎ²3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis. Nature Medicine, 2001, 7, 1041-1047.	30.7	273
107	Thy-1 binds to integrin Î²3 on astrocytes and triggers formation of focal contact sites. Current Biology, 2001, 11, 1028-1038.	3.9	143
108	The Alternatively Spliced Domain TnFnIII A1A2 of the Extracellular Matrix Protein Tenascin-C Suppresses Activation-Induced T Lymphocyte Proliferation and Cytokine Production. Journal of Immunology, 2001, 167, 6431-6440.	0.8	48

#	Article	IF	Citations
109	Caspase-induced inactivation of the anti-apoptotic TRAF1 during Fas ligand-mediated apoptosis. FEBS Letters, 2000, 468, 129-133.	2.8	63
110	Tumor necrosis factor: clinical use and mechanisms of action. Drug Resistance Updates, 2000, 3, 271-276.	14.4	9
111	Tenascin-C inhibits Î²1 integrin-dependent T lymphocyte adhesion to fibronectin through the binding of its fnIII 1â€‰â€“â€‰5 repeats to fibronectin. European Journal of Immunology, 1999, 29, 1435-1447.	2.9	57
112	Urokinase-type plasminogen activator inhibits Î±4Î²1 integrin-mediated T lymphocyte adhesion to fibronectin independently of its catalytic activity. European Journal of Immunology, 1999, 29, 3196-3209.	2.9	4
113	Evidence for the involvement of endotheliai cell integrin Î±VÎ²3 in the disruption of the tumor vascuiature induced by TNF and IFN-Î³. Nature Medicine, 1998, 4, 408-414.	30.7	441
114	Pulse treatment of human vascular endothelial cells with high doses of tumor necrosis factor and interferon-gamma results in simultaneous synergistic and reversible effects on proliferation and morphology. , 1998, 77, 592-599.		31
115	Clinical applications of TNF-Î± in cancer. Current Opinion in Immunology, 1998, 10, 573-580.	5.5	227
116	Role of Integrins and Evidence for two Distinct Mechanisms Mediating Human Colorectal Carcinoma Cell Interaction with Peritoneal Mesothelial Cells and Extracellular Matrix. Cell Adhesion and Communication, 1997, 4, 439-455.	1.7	24
117	SYSTEMIC RELEASE OF SOLUBLE TNF RECEPTORS AFTER HIGH-DOSE TNF IN ISOLATED LIMB PERFUSION. Cytokine, 1997, 9, 1034-1042.	3.2	17
118	Rapid increase in plasma tenascin-C concentration after isolated limb perfusion with high-dose tumor necrosis factor (TNF), interferon gamma (IFNÎ³) and melphalan for regionally advanced tumors. International Journal of Cancer, 1995, 63, 665-672.	5.1	14
119	Sequence of a human transcript expressed in T-lymphocytes and encoding a fibrinogen-like protein. Gene, 1995, 160, 257-262.	2.2	42